Application of treasure pill in preparation of medicine for preventing cerebral apoplexy

Abstract

The invention provides application of treasure pills in preparation of a medicine for preventing cerebral apoplexy, and relates to the technical field of medicines. The treasure pill is applied to preparation of a medicine for preventing cerebral apoplexy. The invention discovers and verifies that the treasure pill can simultaneously control a plurality of cerebral apoplexy risk factors such as homocysteine, triglyceride, low-density lipoprotein and total cholesterol. For various risk factors of cerebral apoplexy which can be intervened by medicines, the prevention scheme is simple and convenient, the total cost is low, and the medicine has the advantage of reducing or adjusting various risk factors when being used for preventing cerebral apoplexy, especially for primary prevention.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an application of Zhenbao Pills in preparing a medicine for preventing cerebral stroke. Background Art

[0002] Stroke (acute cerebrovascular disease) is a general term for acute attacks of brain diseases caused by vascular damage to the brain. It is a series of diseases caused by ischemic and hypoxic brain tissue due to blood vessel blockage or rupture, which in turn causes neuronal damage or death, including ischemic stroke, hemorrhagic stroke and subarachnoid hemorrhage.

[0003] Stroke prevention: related drugs and their effects, and their application in prevention and treatment

[0004] Stroke-related drugs either control stroke risk factors or prevent thrombosis, all of which play a preventive role in stroke to varying degrees.

[0005] 1. Lowering blood pressure, lipids, and blood sugar: Traditional drugs for treating the "three highs"

[0006] According to the "Guidelines for Rational Use of Hypertension Medication in China 2018," commonly used antihypertensive drugs in clinical practice include angiotensin-converting enzyme inhibitors (ACELs), calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), diuretics, and adrenergic receptor blockers. These drugs prevent stroke by lowering blood pressure. A meta-analysis shows that for every 10 mmHg reduction in systolic blood pressure, antihypertensive drugs reduce the risk of stroke by 26%. This reduction is 26% for primary prevention and 25% for secondary prevention. Long-term blood pressure reduction also reduces cardiovascular and cerebrovascular endpoints and overall mortality. The China Stroke Primary Prevention Trial (CSPPT) suggests that ineffective control of common risk factors in hypertensive patients hinders achieving blood pressure targets in the short, medium, and long term.

[0007] Hypercholesterolemia increases the risk of stroke. -1 It can reduce the risk of stroke by 21%. The IMPROVE-IT study showed that the combination of statins and cholesterol absorption inhibitors can reduce the risk of stroke by 14%.

[0008] Diabetes increases the risk of stroke. However, some glucose-lowering drugs reduce stroke risk in patients with type 2 diabetes; others only reduce cardiovascular risk without reducing stroke risk, and some have no effect on either risk. The Cardiovascular Outcomes Trial in Type 2 Diabetes (SUSTAIN-6) showed that once-weekly injections of the same glucose-lowering drug reduced the risk of a composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 26% and the risk of nonfatal stroke by 39%, but oral formulations did not show this effect.

[0009] Dyslipidemia [Guidelines]

[0010] 1. Adults over 20 years of age should have their fasting lipid profile measured at least once every five years, including total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Men over 40 years of age and postmenopausal women should undergo annual lipid profile testing and assess their 10-year atherosclerotic cardiovascular disease (ASCVD) risk. Individuals at high risk for ischemic cardiovascular disease and ischemic stroke should have their lipid profile measured every three to six months. Patients hospitalized for ischemic cardiovascular disease should have their lipid profile measured upon admission or within 24 hours.

[0011] 2. Based on the individual ASCVD risk level, lowering LDL-C levels should be the primary intervention target, and intervention measures of varying intensities should be adopted.

[0012] 3. For patients at very high risk for ASCVD, the LDL-C target for statin therapy should be <1.8 mmol / L or a ≥50% reduction; for patients at high risk, the LDL-C target should be <2.6 mmol / L or a 50% reduction; and for patients at intermediate and low risk, the LDL-C target should be <3.4 mmol / L.

[0013] 4. Clinical lipid-lowering targets must be achieved, emphasizing that all individuals should maintain a lifelong heart-healthy lifestyle. Statins are the preferred medication for lipid-lowering therapy, with a moderate-strength statin being the initial treatment. The dose should be adjusted appropriately based on individual lipid-lowering efficacy and tolerance. Combination therapy with other lipid-lowering agents should be considered for patients with statin intolerance, substandard cholesterol levels, and severe mixed hyperlipidemia.

[0014] 5. To assess the extent of LDL-C reduction and patient compliance, lipid levels should be rechecked 4 to 12 weeks after initiating statin therapy or adjusting the statin dose, and then every 3 to 12 months.

[0015] 2. Drugs for the treatment of hyperhomocysteinemia

[0016] HyperHcyemia is a common high-risk factor for stroke in my country. Hcy is a sulfhydryl-containing amino acid and an intermediate product in the metabolism of methionine (mainly derived from protein in food). After entering the body, folic acid is metabolized to 5-methyltetrahydrofolate, which remethylates Hcy to methionine by transferring a methyl group, forming a one-carbon cycle, thereby reducing plasma Hcy concentration. The Lancet meta-analysis showed that in patients who supplemented with folic acid during treatment, when Hcy was reduced by more than 20%, the risk of stroke was reduced by 18%. The results of the CSPPT study showed that hypertension with elevated plasma Hcy (> 10 μmol·L -1 A combination of medications that simultaneously lowers blood pressure and Hcy significantly reduces the risk of stroke by 23% compared with blood pressure lowering alone. A meta-analysis further confirmed that, for similar patients, fixed-dose combination therapy or combined therapy significantly reduces the absolute risk of cardiovascular and cerebrovascular events by 12.9% compared with blood pressure lowering alone.

[0017] Hyperhomocysteinemia [Guidelines]

[0018] 1. When screening for stroke risk factors, plasma homocysteine ​​is recommended as a routine screening item if conditions permit.

[0019] 2. For patients with hyperhomocysteinemia, prevention of stroke can be considered by supplementing folic acid or folic acid combined with vitamin B6 and vitamin B12.

[0020] Western medicine has significant limitations for some stroke risk factors that can be treated with medication. Some medications that effectively control stroke risk factors, such as certain lipid-lowering drugs, can increase HDL-C but have no effect on preventing stroke. Certain medications can lower triglycerides, but their effectiveness in preventing stroke has not been proven. Furthermore, the clinical application of antiplatelet or anticoagulant therapy often requires balancing risks (bleeding side effects) with benefits, making it more difficult to manage.

[0021] The pathogenesis of stroke is complex and multifactorial, so controlling a single risk factor alone often yields insufficient benefits. The World Health Organization (WHO) recommends a shift in treatment for stroke from single risk factor treatment to comprehensive cardiovascular risk factor control.

[0022] Due to ethnicity, dietary habits and other reasons, it is more common for hypertensive patients in my country to have high Hcy. Therefore, the development of a multi-effect fixed compound for combined blood pressure and Hcy reduction can help prevent stroke and reduce the risk of other vascular events. Both China and foreign countries are targeting national conditions and disease spectrum, and can be said to have similar goals, jointly promoting a compound drug treatment model that controls multiple cardiovascular risk factors. In addition, compound drugs can simplify treatment plans and reduce total costs, making them more advantageous for the prevention and treatment of chronic diseases (see Stampfer M, Willett W. Folate supplements for stroke prevention targeted trial trumps the rest [J] JAMA. 2015, 313 (13): 1321-1322.). However, the development of new drugs is time-consuming and expensive, and they also need to pass safety evaluation and clinical verification. Therefore, the prevention of stroke should also focus on existing safe and effective Chinese and Mongolian medicines. Summary of the Invention

[0023] In order to solve the technical problems existing in the prior art, the present invention provides an embodiment of the invention for the use of Zhenbao Pills in the preparation of a drug for preventing stroke. The technical solution is as follows:

[0024] Use of Zhenbao Pills in the preparation of medicines for preventing stroke.

[0025] Optionally, the Zhenbao Pills are made from the following medicines in parts by weight:

[0026] 15 parts of gypsum, 10 parts of cloves, 15 parts of terminalia chebula, 15 parts of fructus chuanxiong, 15 parts of fructus magnitzii, 15 parts of safflower, 10 parts of myristica fragrans, 15 parts of white cardamoms, 10 parts of cassia seeds, 15 parts of tsaoko seeds, 10 parts of flax seeds, 15 parts of maple resins, 10 parts of elecampane, 10 parts of the rose hips, 10 parts of liquorice, 15 parts of santalin, 15 parts of dalbergia odorifera, 10 parts of herba euphorbiae, 10 parts of white giant wins, 10 parts of black seed seeds, 10 parts of square seaweed, 15 parts of sea sand, 15 parts of agarwood, 10 parts of long piper longum, 10 parts of cinnamon bark, 0.5 part of musk, 5 parts of bezoars, 20 parts of pearl (system), 30 parts of buffalo horn concentrated powder.

[0027] Optionally, the drug for preventing stroke is a drug for primary prevention of stroke.

[0028] Optionally, the drug for preventing stroke can improve multiple risk factors for stroke, including low-density lipoprotein, triglycerides, homocysteine, and total cholesterol.

[0029] Optionally, the method of administering the drug for preventing stroke is to administer it every day for 15 consecutive days during the stroke-prone season, wherein the stroke-prone season is from September of each year to April of the following year.

[0030] A medicine for preventing stroke, comprising: Zhenbao Pills.

[0031] Optionally, the Zhenbao Pills are made from the following medicines in parts by weight:

[0032] 15 parts of gypsum, 10 parts of cloves, 15 parts of terminalia chebula, 15 parts of fructus chuanxiong, 15 parts of fructus magnitzii, 15 parts of safflower, 10 parts of myristica fragrans, 15 parts of white cardamoms, 10 parts of cassia seeds, 15 parts of tsaoko seeds, 10 parts of flax seeds, 15 parts of maple resins, 10 parts of elecampane, 10 parts of the rose hips, 10 parts of liquorice, 15 parts of santalin, 15 parts of dalbergia odorifera, 10 parts of herba euphorbiae, 10 parts of white giant wins, 10 parts of black seed seeds, 10 parts of square seaweed, 15 parts of sea sand, 15 parts of agarwood, 10 parts of long piper longum, 10 parts of cinnamon bark, 0.5 part of musk, 5 parts of bezoars, 20 parts of pearl (system), 30 parts of buffalo horn concentrated powder.

[0033] Optionally, the drug for preventing stroke is a drug for primary prevention of stroke.

[0034] Optionally, the drug for preventing stroke can improve multiple risk factors for stroke, including low-density lipoprotein, triglycerides, homocysteine, and total cholesterol.

[0035] Optionally, the method of administering the drug for preventing stroke is to administer it every day for 15 consecutive days during the stroke-prone season, wherein the stroke-prone season is from September of each year to April of the following year.

[0036] The beneficial effects brought about by the technical solution provided by the embodiment of the present invention include at least:

[0037] Zhenbao Pills (Eridun-Niaoerle) were first recorded in the 13th-century Manag Mudige Porenwa (Secret Supplement), and were subsequently included in various Mongolian medical works such as the Four Volumes of Ganlu of Mongolian Medicine, the Golden Plaque of Mongolian Medicine, and the Joy of the Observer. It is a traditional and classic Mongolian medicine. Nearly 200 documents on the clinical use of Zhenbao Pills exist, demonstrating its efficacy in promoting qi and blood circulation, clearing heat and calming the mind, relaxing tendons and activating collaterals, and benefiting the internal organs. It cures various intractable conditions such as hemiplegia, nerve paralysis, neurasthenia, muscle and tendon atrophy, and chronic illnesses. It is also primarily used to treat black vein disease, white vein disease, and "Xie Ri Niao Su" disease, and is highly effective in treating cardiovascular and cerebrovascular diseases, among other ailments.

[0038] Previous studies have focused on the therapeutic effects of Zhenbao Pills on stroke, but no studies have reported on their preventive effects. There is also a technical bias in existing technologies that suggests Zhenbao Pills cannot be used to prevent stroke.

[0039] This study investigates the comprehensive effects of the Mongolian medicine Zhenbao Pill on stroke risk factors and demonstrates its effectiveness in primary stroke prevention. This study demonstrates for the first time that Zhenbao Pill can simultaneously control multiple stroke risk factors, including homocysteine, triglycerides, low-density lipoprotein cholesterol, and total cholesterol. This approach offers the advantage of reducing or regulating multiple drug-modifiable stroke risk factors, combined with a simple and cost-effective prevention regimen, for stroke prevention, particularly for primary stroke prevention.

[0040] The prevention model of the present invention is to take 15 Zhenbao pills orally once a day for 15 days during the stroke-prone season, which can maintain safe levels of homocysteine ​​and blood lipids for more than 10 months. The Zhenbao pills of the present invention are highly effective and sustainable in preventing stroke. After 15 days of medication, the levels of homocysteine, triglycerides, and low-density lipoprotein are rapidly and simultaneously reduced, and maintained at normal levels for a long time (about 1 year). The present invention has a tendency to reduce the total cholesterol blood level with continuous use. The Zhenbao pills of the present invention have a delayed effect of drug efficacy. When tested one year after medication, the blood concentrations of low-density lipoprotein and total cholesterol are significantly lower than the levels in the year of medication.

[0041] The Zhenbao Pills of the present invention have a preventive effect on stroke and simultaneously control multiple stroke risk factors, including low-density lipoprotein, glycerate, homocysteine, and total cholesterol. DETAILED DESCRIPTION

[0042] The technical solutions of the present invention are described below in conjunction with embodiments.

[0043] The purpose of the present invention is to seek a multi-target, highly effective and easy-to-use preventive drug for stroke risk factors.

[0044] The Zhenbao Pills are prepared from the following medicines in parts by weight:

[0045] 15 parts of gypsum, 10 parts of cloves, 15 parts of terminalia chebula, 15 parts of fructus chuanxiong, 15 parts of fructus magnitzii, 15 parts of safflower, 10 parts of myristica fragrans, 15 parts of white cardamoms, 10 parts of cassia seeds, 15 parts of tsaoko seeds, 10 parts of flax seeds, 15 parts of maple resins, 10 parts of elecampane, 10 parts of the rose hips, 10 parts of liquorice, 15 parts of santalin, 15 parts of dalbergia odorifera, 10 parts of herba euphorbiae, 10 parts of white giant wins, 10 parts of black seed seeds, 10 parts of square seaweed, 15 parts of sea sand, 15 parts of agarwood, 10 parts of long piper longum, 10 parts of cinnamon bark, 0.5 part of musk, 5 parts of bezoars, 20 parts of pearl (system), 30 parts of buffalo horn concentrated powder.

[0046] Formula and Efficacy: Zhenbao Pills' ingredients, such as costus root, musk, agarwood, dalbergia odorifera, and cloves, promote blood circulation and blood stasis, inhibiting platelet surface activity and aggregation, increasing plasminogen activator activity and microcirculation, and oxygenating injured tissues and nerve cells, promoting repair. Zhenbao Pills also dispel wind and activate meridians. According to Chinese and Mongolian medical theory, ischemic stroke is caused by phlegm entering the meridians and blocking the brain's blood vessels. Zhenbao Pills' ingredients, such as water buffalo horn concentrate powder, soothe convulsions and dispel wind, while sea sand, long pipe, and nutmeg calm and dispel phlegm, dispel wind and unclog the meridians, alleviating symptoms caused by internal phlegm obstruction and blood vessel stasis. Furthermore, by dispelling wind and activating meridians, they improve local tissue oxygenation and promote healing. Zhenbao Pills also possess heat-clearing and detoxifying properties: bezoar, gardenia, toosendan fruit, water buffalo horn concentrate powder, musk, and herba euphorbiae have antibacterial, antiviral, anti-inflammatory, and antipyretic properties. Among them, the concentrated powder of buffalo horn clears heat in the meridians and dries up yellow water; gardenia clears heat in the blood and treats gout and arthritis caused by the spread of chronic heat; musk eliminates stickiness, clears toxic heat, and opens the orifices; pearl clears heat in the meridians and calms the mind. Together, these herbs clear heat from the meridians and unblock blood circulation.

[0047] Zhenbao Pills have a wide range of indications. They are suitable for: white vein disease, muscular atrophy, myasthenia gravis, motor neuron disease, nerve paralysis, soft tissue contusions such as fractures, sprains, and ligament sprains, osteoarthritis, rheumatism, and rheumatoid arthritis; stroke and stroke sequelae; and various neurological diseases. It is a prescription for orthopedics and traumatology, specifically for cerebrospinal cord damage and muscular atrophy. Tibetan anatomy divides the human meridians into white and black veins. Black veins refer to blood vessels, encompassing the entire circulatory system; white veins refer to the nervous system, encompassing the cerebrum, cerebellum, medulla oblongata, spinal cord, and various nerves. White vein disease refers to a dysfunction or pathological damage of the nervous system. Symptoms typically include facial paralysis, numbness and inability to use the limbs, spasticity, opisthotonos, paralysis, hemiplegia, unconsciousness, head tremors, and aphasia. Meridians are pathways for the flow of qi and blood, fundamental to maintaining human life.

[0048] Zhenbao Pills, a classic traditional Tibetan medicine formula known as Sangpei Nubu Mubu in Tibetan, are derived from the classic Tibetan medicine formula Twenty-five-flavor Pearl Pills, first recorded in the 8th-century Tibetan medical treatise "The Four Medical Classics." Continuously refined and improved by generations of Tibetan medical scientists, it was later included in Gongzhu Yuandan Jiacuo's "Tibetan Medical Clinical Notes." It is a Tibetan medicine treatment for various white vein diseases and one of the most commonly used clinical medications. Zhenbao Pills are effective in treating white vein disease (neuropathic pain).

[0049] Example 1 Stroke Prevention Program

[0050] 1 Materials and Methods

[0051] General Information

[0052] This study enrolled 58 patients with two or more stroke risk factors. Of these, 32 (55.17%) were male and 26 (48.27%) were female. Their ages ranged from 41 to 77 years, with a mean age of (60.83±6.26) years. Their disease duration ranged from 1 to 16 years, with a mean disease duration of (8.23±1.21) years. Comorbidities of varying severity were present in 58 patients, including 27 (46.55%) with elevated homocysteine, 23 (39.66%) with hypercholesterolemia, 25 (43.10%) with hypertriglyceridemia, 18 (31.03%) with hypertension, and 8 (13.79%) with diabetes.

[0053] 2. Prevention

[0054] 2.1. In Hohhot, 58 patients with intermediate and low-risk stroke were screened according to the "Guidelines for Primary Prevention of Cerebrovascular Diseases in China 2015". Eligibility criteria required the presence of multiple risk factors related to stroke etiology, including hypertension, dyslipidemia, diabetes, heart disease, hyperhomocysteinemia, carotid artery stenosis, smoking, alcohol intake, unhealthy diet, abdominal obesity, insufficient physical activity, and psychological factors.

[0055] 2.2. Tests before and after administration: blood pressure, electrocardiogram, cholesterol (TC), high-density lipoprotein (HDL-C), triglycerides (TG), low-density lipoprotein (LDL-C), blood glucose level, homocysteine ​​(Hcy).

[0056] 2.3. Administer the drug for two weeks from September to April of the following year, before the peak of stroke attacks, for three years. Follow-up will be conducted during this period and two years after discontinuation of the drug, and the incidence of stroke will be calculated. SPSS statistical analysis will be used to provide a research report on the effects of Zhenbao Pills on high-risk factors for stroke. This will provide systematic scientific and technological support and reference for research on early stroke prevention and treatment strategies in my country and globally, as well as for more accurate application and improved prevention and treatment efficacy.

[0057] Drugs: Zhenbao pills, purchased from Inner Mongolia Mengyao Co., Ltd.

[0058] Dosage: For patients aged 40-70, take 12-15 tablets each time, every morning for 15 consecutive days. Do not take other lipid-lowering or homocysteine-lowering medications from 5 days before starting this medication until the end of the medication period.

[0059] 3. Experimental results:

[0060] The experimental results are shown in Table 2.

[0061] Table 2 Effects of Zhenbao Pills on Observation Indicators in 2023

[0062]

[0063] Table 3 Effects of 2024 Zhenbao Pills on observed indicators

[0064]

[0065] Table 4 Effects of 2025 Zhenbao Pills on observed indicators

[0066]

[0067] Table 5 Comparison between the two years

[0068]

[0069] Note: P<0.05 indicates that the difference is statistically significant, and P<0.01 indicates that the difference is statistically significant.

[0070] Table 6 Examples of cases with significant therapeutic effects

[0071]

[0072] 3.1 The results of the 2023 study show that

[0073] 3.1.1. Zhenbao Pills can significantly reduce blood homocysteine ​​levels, with p < 0.001 being statistically significant.

[0074] 3.1.2. Zhenbao Pills can significantly reduce blood triglyceride levels, with p < 0.01 being statistically significant.

[0075] 3.1.3. Zhenbao Pills can significantly reduce blood low-density lipoprotein (LDL-C) levels, with p < 0.04, indicating statistical significance.

[0076] 3.1.4. Zhenbao Pills do not affect blood pressure, blood sugar, high-density lipoprotein and total cholesterol levels in the short term.

[0077] 3.2 Three-year research results show

[0078] 3.2.1 Homocysteine ​​(CHY)

[0079] After a single dose in 2023, the mean Chy level returned to normal and continued to decline annually, from 17.50 μmol / L in 2023 to 11.72 μmol / L before medication in 2025. There was a significant difference between the two years (p < 0.005). See Table 5.

[0080] 3.2.2. Triglycerides (TG)

[0081] After one dose of the drug in 2023, the TG level dropped significantly to the normal value of 1.67 mmol / L, and there was no significant decrease in the later period. There was no significant difference in the intra-year comparison.

[0082] 3.2.3. Low-density lipoprotein (LDL)

[0083] The mean LDL value after one dose of the drug in 2023 was close to the normal value. The mean value before the drug in 2024 was the normal value of 2.64 mmol / L. There was no significant decrease in 2025. There was a significant difference in the mean values ​​between 2023 and 2024 and 2025. There was no significant change between 2024 and 2025.

[0084] 3.2.4. Cholesterol (TC)

[0085] 3.2.5. The mean TC value after a single dose in 2023 did not change significantly, but showed a downward trend year by year. There were significant differences among the three years. The results are shown in Table 5.

[0086] 3.2.6. Zhenbao Pills do not affect blood sugar levels.

[0087] 3.2.7 The results of the study showed that Zhenbao Pills can simultaneously reduce the risk factors of stroke: Hcy, TG, LDL-C and TC, thereby playing a preventive role.

[0088] 3.2.8 Zhenbao Pills have a delayed effect. When tested one year after taking the medicine, the blood concentrations of low-density lipoprotein and total cholesterol are significantly lower than the levels in the year of taking the medicine.

[0089] 4. Analysis of Research Results

[0090] 4.1 Studies have shown that taking Zhenbao Pills for 15 days in patients at low or moderate risk of stroke reduced homocysteine ​​levels by 2.83 μmol / L. Based on the assumption that every 1 μmol / L increase in plasma homocysteine ​​increases the risk of ischemic stroke by 20%, this preventive approach can reduce the risk of stroke by 56.6%. The difference before and after treatment was statistically significant. Three years of prevention and observation showed that this approach maintained homocysteine ​​levels at a safe level without the use of other homocysteine-lowering drugs. The results showed that 12 patients (26.67%) had their homocysteine ​​levels reduced from elevated to normal levels. Among these, 10 patients with type H hypertension had homocysteine ​​levels reduced to normal in 6 (60%) patients. Among the volunteers who received the three-year prevention program, only one patient's homocysteine ​​level decreased from 35.67 to 27.20 μmol / L before treatment in 2023, remaining at 26.17 μmol / L in 2025. All others had their homocysteine ​​levels normal before treatment in 2025. Therefore, it is of positive significance to administer Zhenbao Pills preventively during the high-incidence season of stroke.

[0091] 4.2. Relationship between Hyperlipidemia Risk and Numerical Values

[0092] For every 1mmol•L increase in triglycerides -1, the incidence of ischemic stroke increases by 25%. This preventive method can reduce the average TG level by 0.40 mol•L -1 , the incidence of ischemic stroke decreased by 10.00%.

[0093] Lipid-lowering drugs reduce low-density lipoprotein (LDL-C) by 1 μmmol·L -1 , which can reduce the risk of stroke by 21% (see the literature Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention[J]. Lancet Neurod, 2009, 8(5): 453-463). This preventive method can reduce low-density lipoprotein (LDL-C) by an average of 290μmol / L, and its effect in reducing the risk of stroke is obvious.

[0094] For every 1mmol•L increase in total cholesterol -1 , the incidence of stroke increased by 25%; Zhenbao Pills can make the total cholesterol show a downward trend year by year, with the average value from 5.37 mmol•L in 2023 to 5.37 mmol•L in 2024. -1 Reduced to 4.53 mmol•L in 2025 -1 , their risk was reduced by 21%.

[0095] The three-year prevention results showed that taking the medicine once a year for 15 days for three consecutive years significantly reduced the blood levels of homocysteine, low-density lipoprotein, triglycerides and total cholesterol, played a role in reducing the risk factors of stroke, and thus prevented the occurrence of stroke.

[0096] For patients with hyperhomocysteinemia, regular use of Zhenbao Pills can be considered for stroke prevention, especially during the peak stroke season from September to April.

[0097] This study shows that Zhenbao Pills can quickly and simultaneously lower homocysteine, triglyceride, and low-density lipoprotein levels. Comparison of data before medication in 2023 and 2024 shows that it can lower cholesterol levels. Due to the control of multiple targets of stroke risk factors, it reduces the risk of stroke, thereby playing a role in preventing stroke.

[0098] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in the present invention should be included in the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection of the claims.

Claims

1. Application of Zhenbao Pills in the preparation of medicines for preventing stroke.

2. The use according to claim 1, characterized in that The Zhenbao Pills are prepared from the following medicines in parts by weight: 15 parts of gypsum, 10 parts of cloves, 15 parts of terminalia chebula, 15 parts of fructus chuanxiong, 15 parts of fructus magnitzii, 15 parts of safflower, 10 parts of myristica fragrans, 15 parts of white cardamoms, 10 parts of cassia seeds, 15 parts of tsaoko seeds, 10 parts of flax seeds, 15 parts of maple resins, 10 parts of elecampane, 10 parts of the rose hips, 10 parts of liquorice, 15 parts of santalin, 15 parts of dalbergia odorifera, 10 parts of herba euphorbiae, 10 parts of white giant wins, 10 parts of black seed seeds, 10 parts of square seaweed, 15 parts of sea sand, 15 parts of agarwood, 10 parts of long piper longum, 10 parts of cinnamon bark, 0.5 part of musk, 5 parts of bezoars, 20 parts of pearl (system), 30 parts of buffalo horn concentrated powder.

3. The use according to claim 1, characterized in that The drug for preventing stroke is a drug for primary prevention of stroke.

4. The use according to claim 1, characterized in that The drug for preventing stroke can improve multiple risk factors for stroke, including low-density lipoprotein, triglyceride, homocysteine, and total cholesterol.

5. The use according to claim 1, characterized in that The method for administering the drug for preventing stroke is to administer the drug every day for 15 consecutive days during the stroke-prone season, wherein the stroke-prone season is from September of each year to April of the following year.

6. A drug for preventing stroke, characterized in that: It includes: Treasure pills.

7. The drug for preventing stroke according to claim 6, characterized in that The Zhenbao Pills are prepared from the following medicines in parts by weight: 15 parts of gypsum, 10 parts of cloves, 15 parts of terminalia chebula, 15 parts of fructus chuanxiong, 15 parts of fructus magnitzii, 15 parts of safflower, 10 parts of myristica fragrans, 15 parts of white cardamoms, 10 parts of cassia seeds, 15 parts of tsaoko seeds, 10 parts of flax seeds, 15 parts of maple resins, 10 parts of elecampane, 10 parts of the rose hips, 10 parts of liquorice, 15 parts of santalin, 15 parts of dalbergia odorifera, 10 parts of herba euphorbiae, 10 parts of white giant wins, 10 parts of black seed seeds, 10 parts of square seaweed, 15 parts of sea sand, 15 parts of agarwood, 10 parts of long piper longum, 10 parts of cinnamon bark, 0.5 part of musk, 5 parts of bezoars, 20 parts of pearl (system), 30 parts of buffalo horn concentrated powder.

8. The drug for preventing stroke according to claim 6, characterized in that The drug for preventing stroke is a drug for primary prevention of stroke.

9. The drug for preventing stroke according to claim 6, characterized in that The drug for preventing stroke can improve multiple risk factors for stroke, including low-density lipoprotein, triglyceride, homocysteine, and total cholesterol.

10. The drug for preventing stroke according to claim 6, characterized in that The method for administering the drug for preventing stroke is to administer the drug every day for 15 consecutive days during the stroke-prone season, wherein the stroke-prone season is from September of each year to April of the following year.

Images